You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • AB0696 Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in auvergne (france)

Article info

Article menu

Download PDFPDF

Abstracts Accepted for Publication
Spondyloarthritis - treatment
AB0696 Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in auvergne (france)
Free

Authors

Citation

Soubrier M, Castagné B, Pereira B, et al
AB0696 Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in auvergne (france)
Annals of the Rheumatic Diseases 2017;76:1297.

Publication history

  • First published June 15, 2017.
Online issue publication 
January 09, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions